Oncolytics Biotech Inc. (ONC.TO)
CAD 0.83
(-5.68%)
CAD 0.83
(-5.68%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 11.25 Million CAD | 3.92% |
| 2022 | 10.83 Million CAD | 10.74% |
| 2021 | 9.78 Million CAD | 1.97% |
| 2020 | 9.59 Million CAD | -51.47% |
| 2019 | 19.76 Million CAD | 127.98% |
| 2018 | 8.66 Million CAD | -12.13% |
| 2017 | 9.86 Million CAD | 142.5% |
| 2016 | 4.06 Million CAD | 50.16% |
| 2015 | 2.7 Million CAD | -19.69% |
| 2014 | 3.37 Million CAD | -43.85% |
| 2013 | 6 Million CAD | -17.59% |
| 2012 | 7.29 Million CAD | 12.1% |
| 2011 | 6.5 Million CAD | 160.1% |
| 2010 | 2.5 Million CAD | -43.5% |
| 2009 | 4.42 Million CAD | -2.38% |
| 2008 | 4.53 Million CAD | 60.71% |
| 2007 | 2.82 Million CAD | 1.98% |
| 2006 | 2.76 Million CAD | 50.15% |
| 2005 | 1.84 Million CAD | 67.61% |
| 2004 | 1.09 Million CAD | 6.22% |
| 2003 | 1.03 Million CAD | -26.61% |
| 2002 | 1.41 Million CAD | -54.78% |
| 2001 | 3.11 Million CAD | 78.92% |
| 2000 | 1.74 Million CAD | 638.27% |
| 1999 | 236.1 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 11.78 Million CAD | 4.65% |
| 2024 Q2 | 13.75 Million CAD | 16.78% |
| 2023 Q1 | 9.57 Million CAD | -11.59% |
| 2023 FY | 11.25 Million CAD | 3.92% |
| 2023 Q4 | 11.25 Million CAD | -34.06% |
| 2023 Q3 | 17.07 Million CAD | 75.5% |
| 2023 Q2 | 9.72 Million CAD | 1.57% |
| 2022 Q4 | 10.83 Million CAD | 2.55% |
| 2022 Q1 | 9.43 Million CAD | -3.58% |
| 2022 Q2 | 9.46 Million CAD | 0.37% |
| 2022 FY | 10.83 Million CAD | 10.74% |
| 2022 Q3 | 10.56 Million CAD | 11.58% |
| 2021 Q1 | 9.51 Million CAD | -0.85% |
| 2021 Q2 | 9.82 Million CAD | 3.28% |
| 2021 Q3 | 9.88 Million CAD | 0.6% |
| 2021 Q4 | 9.78 Million CAD | -1.01% |
| 2021 FY | 9.78 Million CAD | 1.97% |
| 2020 FY | 9.59 Million CAD | -51.47% |
| 2020 Q4 | 9.59 Million CAD | -6.6% |
| 2020 Q2 | 10.61 Million CAD | -4.55% |
| 2020 Q3 | 10.27 Million CAD | -3.24% |
| 2020 Q1 | 11.12 Million CAD | -43.74% |
| 2019 Q1 | 10.76 Million CAD | 24.12% |
| 2019 Q3 | 12.83 Million CAD | 11.46% |
| 2019 Q4 | 19.76 Million CAD | 54.01% |
| 2019 FY | 19.76 Million CAD | 127.98% |
| 2019 Q2 | 11.51 Million CAD | 7.0% |
| 2018 Q1 | 9.38 Million CAD | -4.89% |
| 2018 FY | 8.66 Million CAD | -12.13% |
| 2018 Q4 | 8.66 Million CAD | -4.73% |
| 2018 Q3 | 9.1 Million CAD | -6.44% |
| 2018 Q2 | 9.72 Million CAD | 3.65% |
| 2017 Q3 | 2.78 Million CAD | -15.98% |
| 2017 FY | 9.86 Million CAD | 142.5% |
| 2017 Q1 | 3.34 Million CAD | -17.69% |
| 2017 Q4 | 9.86 Million CAD | 254.67% |
| 2017 Q2 | 3.31 Million CAD | -1.13% |
| 2016 Q1 | 2.55 Million CAD | -5.73% |
| 2016 Q2 | 2.78 Million CAD | 8.86% |
| 2016 Q3 | 2.8 Million CAD | 1.02% |
| 2016 Q4 | 4.06 Million CAD | 44.84% |
| 2016 FY | 4.06 Million CAD | 50.16% |
| 2015 Q4 | 2.7 Million CAD | -17.3% |
| 2015 Q1 | 4.27 Million CAD | 26.69% |
| 2015 FY | 2.7 Million CAD | -19.69% |
| 2015 Q3 | 3.27 Million CAD | 7.12% |
| 2015 Q2 | 3.05 Million CAD | -28.45% |
| 2014 Q4 | 3.37 Million CAD | 2.29% |
| 2014 Q2 | 3.66 Million CAD | -24.13% |
| 2014 Q1 | 4.83 Million CAD | -19.56% |
| 2014 FY | 3.37 Million CAD | -43.85% |
| 2014 Q3 | 3.29 Million CAD | -10.05% |
| 2013 Q2 | 5.42 Million CAD | -3.57% |
| 2013 Q1 | 5.62 Million CAD | -22.85% |
| 2013 Q4 | 6 Million CAD | 22.29% |
| 2013 Q3 | 4.91 Million CAD | -9.42% |
| 2013 FY | 6 Million CAD | -17.59% |
| 2012 Q1 | 6.07 Million CAD | -6.64% |
| 2012 Q4 | 7.29 Million CAD | 8.64% |
| 2012 FY | 7.29 Million CAD | 12.1% |
| 2012 Q2 | 5.3 Million CAD | -12.67% |
| 2012 Q3 | 6.71 Million CAD | 26.56% |
| 2011 Q1 | 2.33 Million CAD | -6.45% |
| 2011 FY | 6.5 Million CAD | 160.1% |
| 2011 Q4 | 6.5 Million CAD | 87.03% |
| 2011 Q3 | 3.47 Million CAD | -16.93% |
| 2011 Q2 | 4.18 Million CAD | 78.95% |
| 2010 Q2 | 3.63 Million CAD | 24.11% |
| 2010 Q3 | 1.8 Million CAD | -50.27% |
| 2010 Q4 | 2.5 Million CAD | 38.17% |
| 2010 FY | 2.5 Million CAD | -43.5% |
| 2010 Q1 | 2.93 Million CAD | -30.62% |
| 2009 Q2 | 3.22 Million CAD | -24.46% |
| 2009 FY | 4.42 Million CAD | -2.38% |
| 2009 Q4 | 4.22 Million CAD | 35.64% |
| 2009 Q3 | 3.11 Million CAD | -3.46% |
| 2009 Q1 | 4.27 Million CAD | -5.75% |
| 2008 Q3 | 2.8 Million CAD | -32.45% |
| 2008 FY | 4.53 Million CAD | 60.71% |
| 2008 Q1 | 2.75 Million CAD | -2.45% |
| 2008 Q2 | 4.14 Million CAD | 50.66% |
| 2008 Q4 | 4.53 Million CAD | 61.88% |
| 2007 Q2 | 2.37 Million CAD | -16.61% |
| 2007 Q3 | 2.29 Million CAD | -3.28% |
| 2007 FY | 2.82 Million CAD | 1.98% |
| 2007 Q1 | 2.84 Million CAD | 3.0% |
| 2007 Q4 | 2.82 Million CAD | 22.77% |
| 2006 Q2 | 2.05 Million CAD | -5.04% |
| 2006 FY | 2.76 Million CAD | 50.15% |
| 2006 Q4 | 2.76 Million CAD | 10.02% |
| 2006 Q3 | 2.51 Million CAD | 22.25% |
| 2006 Q1 | 2.16 Million CAD | 17.56% |
| 2005 Q1 | 1.41 Million CAD | 28.93% |
| 2005 Q3 | 1.83 Million CAD | 8.34% |
| 2005 Q2 | 1.69 Million CAD | 19.48% |
| 2005 Q4 | 1.84 Million CAD | 0.43% |
| 2005 FY | 1.84 Million CAD | 67.61% |
| 2004 Q1 | 2.14 Million CAD | 107.34% |
| 2004 Q2 | 1.06 Million CAD | -50.21% |
| 2004 Q3 | 1.52 Million CAD | 42.62% |
| 2004 Q4 | 1.09 Million CAD | -27.86% |
| 2004 FY | 1.09 Million CAD | 6.22% |
| 2003 Q1 | 1.01 Million CAD | -28.15% |
| 2003 Q2 | 812 Thousand CAD | -19.87% |
| 2003 Q3 | 1.01 Million CAD | 24.51% |
| 2003 Q4 | 1.03 Million CAD | 2.36% |
| 2003 FY | 1.03 Million CAD | -26.61% |
| 2002 Q1 | 1.58 Million CAD | -49.27% |
| 2002 Q3 | 1.05 Million CAD | -14.65% |
| 2002 Q4 | 1.41 Million CAD | 33.83% |
| 2002 FY | 1.41 Million CAD | -54.78% |
| 2002 Q2 | 1.23 Million CAD | -21.96% |
| 2001 FY | 3.11 Million CAD | 78.92% |
| 2001 Q1 | 1.5 Million CAD | -13.92% |
| 2001 Q4 | 3.11 Million CAD | -3.09% |
| 2001 Q2 | 1.97 Million CAD | 31.72% |
| 2001 Q3 | 3.21 Million CAD | 62.83% |
| 2000 Q4 | 1.74 Million CAD | -28.52% |
| 2000 Q2 | 2.46 Million CAD | 77.14% |
| 2000 FY | 1.74 Million CAD | 638.27% |
| 2000 Q1 | 1.38 Million CAD | 0.0% |
| 2000 Q3 | 2.43 Million CAD | -0.89% |
| 1999 FY | 236.1 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | 9.329% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | 55.935% |
| Helix BioPharma Corp. | 1.57 Million CAD | -612.92% |
| Microbix Biosystems Inc. | 11.02 Million CAD | -2.072% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | 19.264% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -210.624% |
| Sernova Corp. | 9.59 Million CAD | -17.355% |